Endometriosis: Epidemiology Forecast to 2030

The diagnosed prevalent cases of endometriosis in the seven major markets (7MM) are expected to decrease from 3,317,609 cases in 2020 at a negative annual growth rate (AGR) of more than 0.20% by 2030. In 2030, the US will have the highest number of diagnosed prevalent cases of endometriosis in the 7MM, whereas Japan will have the fewest diagnosed prevalent cases.

Endometriosis is the second most common benign gynecological. According to the World Health Organization (WHO), women with endometriosis experience debilitating pain that prevents them from going to work or school, leading to significant social, public health, and economic implications. Nevertheless, there are multiple challenges in achieving a timely diagnosis of endometriosis. First, women with endometriosis have no pathognomonic features or biomarkers necessary and sufficient to define endometriosis. Rather, key symptoms that currently prompt surgical evaluation, such as pain and infertility, can have multiple causes. Second, there is a weak correlation between symptoms and severity or extent of disease, as quantified by the current staging system. Third, diagnostic laparoscopy is required to make a definitive diagnosis of endometriosis; this is only indicated, however, if surgical treatment is to occur concurrently. A delay of approximately seven years has been reported between the development of symptoms and diagnosis of endometriosis, which significantly impacts the patient’s quality of life.

This report provides an overview of the risk factors, comorbidities, and the global and historical epidemiological trends for endometriosis in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).

What are the diagnosed incident cases of endometriosis by status?

In 2020, out of the diagnosed prevalent cases of endometriosis in the 7MM, confirmed cases (with laparoscopy) contributed the higher proportion with more than 65%, while suspected cases (without laparoscopy) contributed more than 30%. Each of the markets in the 7MM reported a higher proportion of confirmed cases (with laparoscopy), with variations in the specific proportions by market.

What are the diagnosed incident cases of endometriosis by stage?

In 2020, out of the diagnosed prevalent cases of endometriosis in the 7MM, stage IV (severe) contributed the highest proportion with more than 30% cases, while stage I (minimal) contributed more than 25% cases, stage III (moderate) contributed more than 20% cases, and stage II (mild) contributed more than 15% cases. In the 7MM in 2020, the US accounted for the highest number of diagnosed prevalent cases of endometriosis by stage, while Japan had the fewest number of diagnosed prevalent cases of endometriosis by stage.

Diagnosed incident cases of endometriosis by stages

For more insights, download a free report sample

What are the diagnosed incident cases of endometriosis in the 7MM?

In 2020, the US accounted for more than 40% of the diagnosed prevalent cases of endometriosis in the 7MM. There were 1,809,786 cases in the 5EU in 2020, or more than 50% of the diagnosed prevalent cases, while Japan had more than 3% cases. In the 7MM, the diagnosed prevalent cases of endometriosis will decrease by more than 2% over the forecast period at a negative Annual Growth Rate (AGR) of more than 0.2%, from 2020 to 2030. Of the 7MM, the US is expected to have the highest AGR of more than 0.5%, with the diagnosed prevalent cases increasing by 2030. Japan had the lowest number of diagnosed prevalent cases of endometriosis in 2020. Any change in the diagnosed prevalent cases of endometriosis is attributable to changing population demographics in the 7MM.

Diagnosed incident cases of endometriosis in the 7MM, by country

For more regional insights, download a free report sample

Market report scope

Scope

This report provides an in-depth analysis of the following:

• The Endometriosis Epidemiology Report and Model provide an overview of the risk factors and global trends of Endometriosis in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).
• The report includes a 10-year epidemiology forecast for the diagnosed prevalent cases of endometriosis. The diagnosed prevalent cases of endometriosis are segmented by age (12–54 years) and laparoscopy confirmation status (whether suspected or confirmed endometriosis). The report also includes the diagnosed prevalent cases of endometriosis further segmented by ASRM stage and classified as Stage I (Minimal), Stage II (Mild), Stage III (Moderate), or Stage IV (Severe); phenotype: Superficial Peritoneal Endometriosis (SUP), Ovarian Endometrioma (OMA), and Deep Infiltrating Endometriosis (DIE); cases undergoing laparoscopy; and comorbidities such as chronic pelvic pain (CPP), dysmenorrhea, and dyspareunia. The model associated with this report additionally provides diagnosed incident cases segmented by age (12–54 years) and laparoscopy confirmation status (whether suspected or confirmed endometriosis).
• The endometriosis epidemiology report and model were written and developed by Masters- and PhD-level epidemiologists.
• The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.
• The Epidemiology Model is easy to navigate, interactive with dashboards, and epidemiology-based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over a 10-year forecast period using reputable sources.

Reasons to Buy

The Endometriosis Epidemiology series will allow you to:

• Develop business strategies by understanding the trends shaping and driving the global endometriosis market.
• Quantify patient populations in the global endometriosis market to improve product design, pricing, and launch plans.
• Organize sales and marketing efforts by identifying the age groups that present the best opportunities for endometriosis therapeutics in each of the markets covered.
• Understand the magnitude of the endometriosis population by laparoscopy confirmation status and comorbidities.